PTPRS Antibody

What is PTPRS and why is it significant in research contexts?

PTPRS (Protein tyrosine Phosphatase, Receptor Type, S) is a receptor-type tyrosine-protein phosphatase with a molecular mass of approximately 217 kilodaltons. It functions as a critical regulator of signal transduction pathways in various cellular processes. The significance of PTPRS in research stems from its involvement in cell signaling, particularly in pathways that influence cellular differentiation, proliferation, and migration. Understanding PTPRS activity is crucial for exploring its potential role in diseases, including cancer metastasis and neurological disorders. Antibodies targeting PTPRS enable researchers to detect, quantify, and manipulate this protein in experimental settings, providing valuable insights into its physiological and pathological functions .

How do polyclonal and monoclonal PTPRS antibodies differ in research applications?

Polyclonal and monoclonal PTPRS antibodies fundamentally differ in their specificity and application versatility. Polyclonal PTPRS antibodies, such as the rabbit polyclonal antibodies listed in the catalog, recognize multiple epitopes on the PTPRS protein, offering high sensitivity for detection in various applications including ELISA, IHC, and Western blotting . This multi-epitope recognition makes polyclonal antibodies particularly valuable for detecting PTPRS in denatured conditions or when protein expression is low.

In contrast, monoclonal antibodies like the mouse monoclonal 1H6 antibody target a single epitope on PTPRS, providing exceptional specificity but potentially lower sensitivity than polyclonal options . Monoclonal antibodies excel in applications requiring high reproducibility and consistent batch-to-batch performance, such as therapeutic development or standardized diagnostic procedures. Researchers should select between these antibody types based on their experimental goals: polyclonal for broad detection capabilities, and monoclonal for highly specific epitope targeting and reproducible results.

What are the key considerations when selecting a PTPRS antibody for cross-species reactivity studies?

When conducting cross-species reactivity studies with PTPRS antibodies, researchers must carefully evaluate several critical factors. First, sequence homology analysis between target species is essential—PTPRS demonstrates varying conservation across mammals, with some regions being highly conserved while others diverge significantly. The antibody catalog data shows that certain PTPRS antibodies exhibit reactivity across human, mouse, and rat samples, making them suitable for comparative studies .

Researchers should specifically examine the immunogen sequence used to generate the antibody—those targeting highly conserved domains are more likely to cross-react effectively. For instance, antibodies targeting amino acids 320-400 demonstrate reactivity across human, mouse, and rat models . Validation is crucial; preliminary testing should include positive controls from each species to confirm reactivity and determine optimal working dilutions, which may vary between species. Western blotting with tissue lysates from different species can verify antibody specificity before proceeding to more complex applications like immunohistochemistry or immunoprecipitation in cross-species studies.

How should PTPRS antibodies be optimized for immunohistochemistry applications?

Optimizing PTPRS antibodies for immunohistochemistry (IHC) requires a systematic approach to ensure specific and reproducible staining. Begin with antigen retrieval method selection—PTPRS detection typically benefits from heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). Conduct a titration experiment testing antibody dilutions (typically 1:100 to 1:1000) to determine the optimal concentration that maximizes specific signal while minimizing background .

Blocking procedures are crucial—use 5-10% normal serum from the same species as the secondary antibody for 1-2 hours to reduce non-specific binding. For detection systems, consider whether chromogenic (DAB) or fluorescent-based methods are most appropriate for your research question. Include proper controls: positive controls using tissues known to express PTPRS (such as neural tissues or specific cancer cell lines like CAL51), negative controls omitting primary antibody, and isotype controls using non-specific IgG at the same concentration as the PTPRS antibody . Finally, verify staining patterns through comparison with published literature and confirmation using alternative detection methods such as in situ hybridization for PTPRS mRNA.

What are the optimal conditions for using PTPRS antibodies in Western blotting protocols?

For optimal Western blotting with PTPRS antibodies, sample preparation is critical—complete lysis buffers containing both ionic detergents (like SDS) and non-ionic detergents (like Triton X-100) maximize PTPRS extraction from membrane fractions. Given the high molecular weight of PTPRS (217 kDa), use low percentage (6-8%) SDS-PAGE gels or gradient gels (4-15%) with extended running time to achieve proper separation .

Transfer conditions should be optimized for large proteins—use wet transfer with low methanol (5-10%) in transfer buffer, at low voltage (30V) for extended periods (overnight) at 4°C. For primary antibody incubation, dilutions typically range from 1:500 to 1:2000 in 5% BSA or milk in TBST, with overnight incubation at 4°C showing superior results to shorter incubations . Include appropriate positive controls such as neural tissue lysates or PTPRS-overexpressing cell lines. For complex samples, consider enrichment steps like immunoprecipitation before Western blotting to enhance detection sensitivity. Detection systems should be selected based on expected expression levels—chemiluminescence offers good sensitivity, while fluorescent detection provides better quantification range for comparative studies.

How can PTPRS antibodies be effectively utilized in immunoprecipitation studies of protein-protein interactions?

For effective immunoprecipitation (IP) of PTPRS to study protein-protein interactions, begin with optimized cell lysis—use non-denaturing buffers containing 1% NP-40 or 0.5% Triton X-100 with protease and phosphatase inhibitors to preserve native protein interactions. Pre-clear lysates with appropriate control beads (Protein A/G) to reduce non-specific binding. Select antibodies specifically validated for IP applications—polyclonal antibodies often perform better in IP due to their recognition of multiple epitopes .

For the IP procedure, use approximately 2-5 μg of antibody per 500 μg of protein lysate, incubating overnight at 4°C with gentle rotation. Consider crosslinking the antibody to beads using dimethyl pimelimidate to prevent antibody contamination in eluted samples. When investigating specific interactions, sequential or co-immunoprecipitation approaches can be employed—for example, when studying SRC interactions with PTPRS as implicated in metastatic signaling . For challenging interactions, consider in situ crosslinking with membrane-permeable crosslinkers (DSP or formaldehyde) prior to lysis. Analysis of immunoprecipitated complexes should include both targeted Western blotting for suspected interaction partners and unbiased approaches such as mass spectrometry to identify novel interactions in the PTPRS interactome.

How can antibodies be used to manipulate PTPRS dimerization and signaling activity?

Manipulating PTPRS dimerization and signaling activity through antibodies represents an advanced research strategy with therapeutic potential. Research demonstrates that antibodies targeting the PTPRS ectodomain can induce dimerization, which modulates its phosphatase activity. The monoclonal antibody approach is exemplified by studies with similar receptor phosphatases like PTPRD, where the antibody RD-43 induced dimerization that inhibited phosphatase activity and promoted receptor degradation .

To implement this strategy with PTPRS, researchers should select antibodies targeting specific extracellular domains, particularly those involved in natural dimerization interfaces. Bivalent antibodies are particularly effective, as they can physically bridge two PTPRS molecules, inducing artificial dimerization. The functional consequences of antibody-induced dimerization should be assessed through phosphatase activity assays, downstream signaling pathway analysis (particularly SRC pathway components), and cellular phenotypic assays relevant to PTPRS function, such as migration or invasion assays in cancer cell models . This approach not only provides valuable research insights but also represents a potential therapeutic strategy in contexts where PTPRS inhibition is desirable.

What methods can be employed to investigate the role of PTPRS in cancer metastasis using specific antibodies?

Investigating PTPRS in cancer metastasis using antibodies requires a multi-faceted approach. Based on research with related phosphatases, PTPRS may function in tumor progression by regulating SRC activity and influencing metastatic potential . To explore this, researchers should first establish PTPRS expression profiles across normal and metastatic tissues using immunohistochemistry with validated antibodies, comparing expression patterns with clinical outcomes data.

In vitro studies should examine PTPRS function using antibody-mediated manipulation—both blocking antibodies to inhibit ligand binding and dimerizing antibodies to modulate phosphatase activity . Functional assays including Transwell invasion, 3D spheroid invasion, and scratch wound healing assays can assess the impact of PTPRS modulation on metastatic behaviors. Phospho-specific antibodies targeting SRC and downstream effectors help elucidate signaling mechanisms. For in vivo studies, antibody-based imaging using fluorescently-labeled anti-PTPRS antibodies can track metastatic cells expressing PTPRS. Additionally, therapeutic potential can be explored through antibody treatment in mouse metastasis models, monitoring for changes in metastatic burden through bioluminescence imaging and histological analysis with PTPRS and phospho-SRC antibodies.

How do experimental conditions affect PTPRS phosphatase activity measurements using immunoprecipitation and activity assays?

The accurate measurement of PTPRS phosphatase activity is highly susceptible to experimental conditions. When immunoprecipitating PTPRS for activity assays, buffer composition is critical—phosphate buffers must be avoided as they inhibit phosphatase activity, while EDTA should be included to inhibit metalloproteinases but removed before activity measurements as it can chelate essential metal ions .

Redox conditions significantly impact PTPRS activity—the catalytic cysteine in the phosphatase domain is sensitive to oxidation, which inactivates the enzyme. Therefore, reducing agents like DTT (1-5 mM) should be included in activity buffers, and all solutions should be deoxygenated. Temperature control is essential, with most assays optimally performed at 30°C rather than 37°C to balance activity with stability. The choice of substrate affects measured activity—artificial substrates like pNPP provide reproducible results but may not reflect physiological specificity, while phosphopeptides derived from natural substrates offer more relevant insights but with lower signal. When comparing PTPRS activity between experimental conditions, careful normalization based on immunoprecipitated PTPRS amounts is essential, using quantitative Western blotting with the same antibody used for immunoprecipitation or an antibody targeting a different epitope .

How can researchers address non-specific binding issues when using PTPRS antibodies in immunofluorescence studies?

Non-specific binding in immunofluorescence studies with PTPRS antibodies can significantly compromise data quality but can be systematically addressed. First, optimize fixation conditions—overfixation with paraformaldehyde (>15 minutes) can create artificial epitopes, while mild fixation (2-4% PFA for 10 minutes) typically preserves PTPRS antigenicity while maintaining structure. Implement comprehensive blocking—use 5-10% normal serum from the secondary antibody species, supplemented with 0.1-0.3% Triton X-100 for permeabilization, and consider adding 1% BSA and 0.1% glycine to quench residual aldehydes from fixation .

Antibody validation is crucial—test each new lot on positive and negative control samples, and perform peptide competition assays where excess immunizing peptide should abolish specific staining. For tissues with high autofluorescence (brain, liver), consider using Sudan Black B (0.1-0.3%) treatment or commercial autofluorescence quenchers. Background from secondary antibodies can be assessed through controls omitting primary antibody, while isotype controls help distinguish between specific binding and Fc receptor interactions. Finally, spectral imaging and unmixing techniques can help separate specific signals from autofluorescence, particularly valuable when working with tissues that naturally exhibit high background fluorescence.

What are the potential causes of inconsistent results between different detection methods when studying PTPRS expression?

Inconsistent results between detection methods for PTPRS expression stem from multiple factors. Epitope accessibility varies substantially across methods—PTPRS antibodies targeting extracellular domains typically perform well in flow cytometry and immunofluorescence of non-permeabilized cells, while antibodies against intracellular domains require effective permeabilization protocols . Different fixation and processing procedures can dramatically affect epitope preservation—formalin fixation for IHC may mask epitopes that are readily detected in frozen sections or mild PFA fixation for IF.

Protocol-specific technical variables also contribute to inconsistencies—the denaturing conditions of Western blotting expose epitopes that may be inaccessible in native-state applications, while the sensitivity of detection systems varies dramatically between chromogenic IHC, fluorescence, and chemiluminescent Western blotting. Quantitative comparisons are further complicated by the dynamic range limitations of different detection methods. To address these discrepancies, researchers should implement a multi-method validation approach—confirm key findings with at least two independent detection methods, use multiple antibodies targeting different PTPRS epitopes, and include appropriate reference standards and controls specific to each detection method .

How should researchers interpret contradictory data on PTPRS expression and function across different cell lines and tissue types?

Interpreting contradictory PTPRS data across cell lines and tissues requires nuanced analysis of biological and technical variables. PTPRS undergoes complex post-translational modifications including N-glycosylation and proteolytic processing that vary between tissues, potentially affecting antibody recognition and protein function . Alternative splicing generates multiple PTPRS isoforms with tissue-specific expression patterns—researchers should determine which isoforms their antibodies detect and whether observed contradictions reflect actual isoform differences.

Cell-type specific binding partners and signaling contexts significantly influence PTPRS function—the protein may exhibit opposing effects in different cellular environments depending on available substrates and regulatory proteins. For example, in neural tissues, PTPRS may primarily regulate axon guidance, while in epithelial cells, it might predominantly affect cell-cell adhesion . Experimental approach standardization is critical when comparing across studies—differences in antibody concentrations, detection methods, and quantification techniques can lead to apparent contradictions that reflect methodological rather than biological differences. To reconcile contradictory findings, researchers should conduct comprehensive literature analyses focusing on experimental details, implement standardized protocols across cell lines being compared, and consider genetic approaches (CRISPR knockout/knockdown followed by rescue with specific isoforms) to definitively establish PTPRS functions in different contexts.

How might antibody-based therapeutic approaches targeting PTPRS be developed for cancer treatment?

Development of antibody-based PTPRS therapeutics for cancer represents an emerging frontier with multiple potential mechanistic approaches. Building on research with related phosphatases like PTPRD, antibodies that induce PTPRS dimerization could inhibit its phosphatase activity, potentially suppressing SRC-dependent metastatic pathways in cancers where PTPRS promotes tumor progression . Alternatively, in cancers where PTPRS functions as a tumor suppressor, agonistic antibodies that enhance PTPRS activity could restore growth control.

For therapeutic development, researchers should first conduct comprehensive screenings of monoclonal antibodies against different PTPRS extracellular domains, assessing their effects on dimerization, phosphatase activity, and downstream signaling. Engineering approaches can enhance therapeutic potential—developing antibody-drug conjugates targeting PTPRS-expressing cancer cells, or creating bispecific antibodies that simultaneously engage PTPRS and immune effector cells. Humanization of promising antibody candidates is essential for clinical translation, alongside toxicity assessment in appropriate animal models. A critical consideration is patient stratification—because PTPRS may have context-dependent roles in different cancers, biomarker development to identify patients likely to benefit from PTPRS-targeting therapies is essential for successful clinical application .

What are the emerging techniques for studying PTPRS phosphatase substrate specificity using immunoprecipitation and mass spectrometry?

Advanced techniques combining immunoprecipitation with mass spectrometry are revolutionizing our understanding of PTPRS substrate specificity. The substrate-trapping approach represents a powerful strategy—researchers can generate catalytically inactive PTPRS mutants (typically D→A mutations in the catalytic site) that bind but do not dephosphorylate substrates, forming stable enzyme-substrate complexes that can be immunoprecipitated using PTPRS antibodies and analyzed by mass spectrometry .

Proximity-dependent biotinylation techniques offer complementary insights—by fusing PTPRS to promiscuous biotin ligases (BioID or TurboID), researchers can biotinylate proteins in close proximity to PTPRS in living cells, followed by streptavidin purification and mass spectrometry to identify the PTPRS proximal proteome. Quantitative phosphoproteomics provides a systems-level view—by comparing phosphotyrosine profiles in cells with and without PTPRS manipulation (knockout, overexpression, or antibody treatment), researchers can identify substrates showing increased phosphorylation upon PTPRS inhibition . These approaches can be combined with structural studies to develop predictive models of PTPRS substrate recognition, facilitating the rational design of substrate-selective PTPRS modulators with potentially improved therapeutic profiles compared to global PTPRS inhibition or activation.

How can single-cell analysis techniques be combined with PTPRS antibodies to understand heterogeneity in phosphatase signaling?

Integrating single-cell analysis with PTPRS antibody-based detection opens new frontiers in understanding phosphatase signaling heterogeneity. For single-cell phospho-flow cytometry, researchers can use fluorescently-conjugated PTPRS antibodies (such as FITC-conjugated anti-PTPRS antibodies) in combination with phospho-specific antibodies targeting potential substrates like SRC . This approach enables quantification of correlations between PTPRS expression and substrate phosphorylation states at the single-cell level, revealing subpopulations with distinct signaling characteristics.

For imaging-based approaches, multiplexed immunofluorescence using anti-PTPRS antibodies alongside phospho-substrate antibodies allows spatial mapping of PTPRS activity domains within tissues or cultured cells. Cyclic immunofluorescence or mass cytometry (CyTOF) with metal-conjugated PTPRS antibodies enables simultaneous detection of dozens of proteins, providing comprehensive signaling network analysis. Single-cell RNA-seq can be complemented with antibody-based PTPRS protein detection through CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing), correlating PTPRS protein levels with transcriptomic signatures at single-cell resolution. These integrated approaches will be particularly valuable in heterogeneous systems like tumors or developing tissues, where PTPRS signaling may vary dramatically between adjacent cells, contributing to diverse cellular behaviors within the same microenvironment .

Table 1: Applications and Sensitivity of Different PTPRS Antibody Types

Data compiled from antibody specifications across multiple suppliers

Table 2: Troubleshooting Guide for Common PTPRS Antibody Experimental Issues